Skip to content

Replimune Group REPL Short- and long-term operating lease liabilities

Short- and long-term operating lease liabilities at other companies

Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's short- and long-term operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's short- and long-term operating lease liabilities?
Replimune Group (REPL) reported short- and long-term operating lease liabilities of -$207K in Q4 2025.
How has Replimune Group's short- and long-term operating lease liabilities changed year-over-year?
Replimune Group's short- and long-term operating lease liabilities decreased by 13.1% year-over-year, from -$183K to -$207K.
What is the long-term trend for Replimune Group's short- and long-term operating lease liabilities?
Over 2 years (2022 to 2025), Replimune Group's short- and long-term operating lease liabilities has grown at a 214.1% compound annual growth rate (CAGR), from -$73K to -$720K.